SCHEMBL771255

SCHEMBL771255

O=C(CCN1C(=O)c2cccc(F)c2C1=O)N1CCC2CCCCC2C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.54
ALDH1A1 P00352 6/20 0.48
HSD17B10 Q99714 4/20 0.48
HPGD P15428 2/20 0.48
KMT2A Q03164 2/20 0.48
GAA P10253 2/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
HTR1A P08908 1/20 0.47
HTR7 P34969 1/20 0.47
HRH1 P35367 1/20 0.47
DRD3 P35462 1/20 0.47
HTR2B P41595 1/20 0.47
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
HTT P42858 1/20 0.46
TP53 P04637 1/20 0.44
KDM4E B2RXH2 1/20 0.43
RAB9A P51151 1/20 0.43
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL771358 0.94 SMN1; SMN2 (0.56) MAPK1ALDH1A1HSD17B10HPGDKMT2A
SCHEMBL771493 0.89 HSD17B10 (0.50) MAPK1ALDH1A1HSD17B10HPGDKMT2A
SCHEMBL770300 0.87 MAPK1 (0.70) MAPK1ALDH1A1HSD17B10HPGDKMT2A
SCHEMBL771729 0.82 SMN1; SMN2 (0.57) MAPK1ALDH1A1HSD17B10HPGDKMT2A
SCHEMBL770980 0.82 ALDH1A1 (0.57) MAPK1ALDH1A1HSD17B10HPGDKMT2A
SCHEMBL772470 0.81 MAPK1 (0.54) MAPK1ALDH1A1HSD17B10HPGDKMT2A
SCHEMBL769680 0.80 SMN1; SMN2 (0.71) MAPK1ALDH1A1HSD17B10HPGDKMT2A
SCHEMBL770678 0.79 ALDH1A1 (0.71) MAPK1ALDH1A1HSD17B10HPGDKMT2A
SCHEMBL770463 0.78 HSD17B10 (0.51) MAPK1ALDH1A1HSD17B10HPGDKMT2A
SCHEMBL771256 0.77 MAPK1 (0.50) MAPK1ALDH1A1HSD17B10HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 MAPK1 401/4885ALDH1A1 144/4885HSD17B10 19/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 MAPK1 410/4885ALDH1A1 142/4885HSD17B10 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.